Lazard Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.02M Sell
6,702
-464
-6% -$71.1K ﹤0.01% 1154
2025
Q4
$988K Buy
7,166
+2,439
+52% +$319K ﹤0.01% 1155
2025
Q3
$606K Hold
4,727
﹤0.01% 1293
2025
Q2
$572K Hold
4,727
﹤0.01% 1452
2025
Q1
$526K Sell
4,727
-59
-1% -$6.28K ﹤0.01% 1396
2024
Q4
$465K Sell
4,786
-506
-10% -$54K ﹤0.01% 1388
2024
Q3
$608K Sell
5,292
-46
-0.9% -$5.22K ﹤0.01% 1304
2024
Q2
$567K Sell
5,338
-606
-10% -$60.8K ﹤0.01% 1160
2024
Q1
$574K Sell
5,944
-485
-8% -$49.7K ﹤0.01% 1029
2023
Q4
$648K Buy
6,429
+5
+0.1% +$483 ﹤0.01% 1049
2023
Q3
$653K Sell
6,424
-800
-11% -$81.2K ﹤0.01% 1078
2023
Q2
$728K Buy
7,224
+735
+11% +$73.5K ﹤0.01% 1043
2023
Q1
$596K Sell
6,489
-82
-1% -$7.16K ﹤0.01% 1079
2022
Q4
$596K Sell
6,571
-1,367
-17% -$115K ﹤0.01% 1086
2022
Q3
$602K Sell
7,938
-3,645
-31% -$302K ﹤0.01% 1069
2022
Q2
$978K Sell
11,583
-1,108,040
-99% -$97.2M ﹤0.01% 1004
2022
Q1
$98.2M Sell
1,119,623
-24,122
-2% -$2.09M 0.11% 163
2021
Q4
$100M Buy
1,143,745
+18,605
+2% +$1.54M 0.11% 173
2021
Q3
$92M Sell
1,125,140
-13,024
-1% -$1.17M 0.1% 187
2021
Q2
$104M Buy
1,138,164
+2,223
+0.2% +$198K 0.12% 157
2021
Q1
$97.1M Sell
1,135,941
-354,713
-24% -$31.8M 0.12% 152
2020
Q4
$141M Sell
1,490,654
-374,806
-20% -$32.8M 0.18% 110
2020
Q3
$162M Sell
1,865,460
-508,581
-21% -$44.1M 0.23% 90
2020
Q2
$207M Sell
2,374,041
-317,469
-12% -$27.4M 0.32% 73
2020
Q1
$222M Buy
2,691,510
+218,813
+9% +$19.5M 0.41% 57
2019
Q4
$234M Sell
2,472,697
-19,215
-0.8% -$1.72M 0.33% 76
2019
Q3
$217M Sell
2,491,912
-10,867
-0.4% -$976K 0.36% 71
2019
Q2
$229M Sell
2,502,779
-316,122
-11% -$26.8M 0.37% 69
2019
Q1
$243M Buy
2,818,901
+87,882
+3% +$7.05M 0.4% 66
2018
Q4
$210M Buy
2,731,019
+646,279
+31% +$50.3M 0.39% 69
2018
Q3
$161M Buy
2,084,740
+50,436
+2% +$3.73M 0.26% 93
2018
Q2
$138M Buy
2,034,304
+31,215
+2% +$2.15M 0.24% 92
2018
Q1
$145M Buy
2,003,089
+134,348
+7% +$10.2M 0.25% 88
2017
Q4
$141M Buy
1,868,741
+103,046
+6% +$7.78M 0.24% 89
2017
Q3
$136M Buy
1,765,695
+18,488
+1% +$1.4M 0.25% 86
2017
Q2
$131M Buy
1,747,207
+18,538
+1% +$1.31M 0.25% 87
2017
Q1
$115M Sell
1,728,669
-714,631
-29% -$47.6M 0.22% 83
2016
Q4
$159M Sell
2,443,300
-189,968
-7% -$12.3M 0.33% 70
2016
Q3
$186M Buy
2,633,268
+97,888
+4% +$7.13M 0.37% 70
2016
Q2
$187M Buy
2,535,380
+37,201
+1% +$2.57M 0.4% 70
2016
Q1
$162M Sell
2,498,179
-68,750
-3% -$4.68M 0.35% 75
2015
Q4
$198M Buy
2,566,929
+10,342
+0.4% +$822K 0.45% 61
2015
Q3
$211M Buy
2,556,587
+67,287
+3% +$5.99M 0.5% 57
2015
Q2
$219M Buy
2,489,300
+116,590
+5% +$10.7M 0.46% 62
2015
Q1
$210M Buy
2,372,710
+82,474
+4% +$7.32M 0.45% 62
2014
Q4
$190M Sell
2,290,236
-1,239
-0.1% -$103K 0.41% 67
2014
Q3
$193M Sell
2,291,475
-68,885
-3% -$5.57M 0.42% 70
2014
Q2
$191M Buy
2,360,360
+92,375
+4% +$7.27M 0.4% 76
2014
Q1
$173M Buy
2,267,985
+197,584
+10% +$14.4M 0.39% 80
2013
Q4
$149M Buy
2,070,401
+60,190
+3% +$4.18M 0.33% 83
2013
Q3
$138M Buy
2,010,211
+32,140
+2% +$2.13M 0.33% 81
2013
Q2
$125M Buy
+1,978,071
New +$129M 0.3% 88

Other funds holding NVS

Lazard Asset Management's NVS Position: Q1 2026 in Review

Lazard Asset Management reduced its Novartis (NVS) stake by 6.5% in Q1 2026, selling an estimated $71.1K and leaving 6,702 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1154.

Lazard Asset Management first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $243M in Q1 2019. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Lazard Asset Management held 6,702 shares of Novartis worth $1.02M as of Q1 2026.
  • Lazard Asset Management sold 464 Novartis shares in Q1 2026, an estimated $71.1K.
  • Novartis made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1154 holding.
  • Lazard Asset Management first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Lazard Asset Management's Novartis position peaked at $243M in Q1 2019.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.